| Project/Area Number |
16591678
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
MIYAGI Etsuko Yokohama City University, Obstetrics, Gynecology and Molecular Reproductive Science, Associate Professor (40275053)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRAHARA Fumiki Yokohama City University, Obstetrics, Gynecology and Molecular Reproductive Science, Professor (30201734)
MIYAGI Yohei Kanagawa Cancer Center Research Institute, Molecular Pathology and Genetics Division, Director (00254194)
|
|---|
| Project Period (FY) |
2004 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥2,650,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥150,000)
Fiscal Year 2007: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2006: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2005: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2004: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | ovarian cancer / adenocarinoma / kallikrein / serine protease / clear cell adenocarcinoma / serous adenocarcinoma / tissue tvne / gene expression |
|---|
| Research Abstract |
【Objectives】 Some kinds of serine proteases are known to play important roles in the process of malignant progression of cancer cells. In addition, prostate specific antigen (PSA) , which is identical to human kallikrein 3, has been an effective biomarker for prostate cancer. However, little is known about the role of kallikrein (KLK) subtypes, which have activities like trypsin and chymotrypsin in the progression of ovarian cancer.
【Methods】Gene expression of KLK subtypes 4,5,6,9,10 and 11 were examined quantitatively using RT-PCR methods in both ovarian cancer cell lines and tissues.
【Results】 (1) In 9 ovarian cancer cell lines and 28 ovarian cancer tissues, KLK 10 gene was revealed to be expressed frequently(cell lines 89%, tissues 100%) and to a high degree. (2) KLK 5 had a tendency to be expressed highly in serous and endometrioid adenocarcinoma tissues compared to clear and mucinous adenocarcinoma. (3) Clear cell adenocarcinoma showed high degree KLK 6 expression and low degree KLK5, 11. In serous adenocarcinoma tissues, KLK 11 was highly expressed compared to the other tissue types. (4) There was no correlation between the gene expression of KLK subtypes and clinical stages or serum CAl25 levels.
【 Conclusions】 It was revealed that ovarian cancer cells express various KLK subtypes. KLK 10 was found to have possibility as a new biomarker of ovarian adenocarcinoma considering very high frequent and high degree gene expression. In addition, various expression patterns of KLK subtypes may relate to specific clinical characteristics in some tissue types of ovarian cancer.
|
